BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 08, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/5 cls
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Piper Jaffray Charles Duncan Upgrade Overweight (from neutral) 3% $4.56
Duncan also raised his target to $10 from $5 on "enhanced conviction" in the near- and long-term market potential for Alexza's Adasuve Staccato loxapine based on optimism from surveyed physicians. Alexza plans to launch Adasuve in next quarter in the U.S. and EU to treat agitation in adults with schizophrenia or bipolar disorder. Duncan estimates $690,000 in Adasuve sales for 2013 and $29.2M in 2014. Grupo Ferrer Internacional S.A. has commercialization rights in Europe to...

Read the full 650 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >